The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse
Open accessPublished version of a preprint
Abstract
Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells acquire a proinflammatory senescence-associated secretory phenotype. Many genotoxic chemotherapies target proliferating cells nonspecifically, often with adverse reactions. In accord with prior work, we show that several chemotherapeutic drugs induce senescence of primary murine and human cells. Using a transgenic mouse that permits tracking and eliminating senescent cells, we show that therapy-induced senescent (TIS) cells persist and contribute to local and systemic inflammation. Eliminating TIS cells reduced several short- and long-term effects of the drugs, including bone marrow suppression, cardiac dysfunction, cancer recurrence, and physical activity and strength. Consistent with our findings in mice, the risk of chemotherapy-induced fatigue was significantly greater in humans with increased expression of a senescence marker in T cells prior to chemotherapy. These findings suggest that senescent cells can cause certain chemotherapy side effects, providing a new target to reduce the toxicity of anticancer treatments. Significance: Many genotoxic chemotherapies have debilitating side effects and also induce cellular senescence in normal tissues. The senescent cells remain chronically present where they can promote local and systemic inflammation that causes or exacerbates many side effects of the chemotherapy. Cancer Discov; 7(2); 165–76. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 115
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, through SASP, senescent cells contribute to cancer development162,163 and metastasis164, treatment failure and increased risk of recurrence165.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [165]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP can also explain chemotherapy side effects, such as bone marrow suppression, cardiac dysfunction, blood clotting, or cancer relapse (Demaria et al. 2017; Wiley et al. 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Demaria et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our study, in accordance with others (Baker et al, 2016; Roos et al, 2016; Demaria et al, 2017), shows that the loss of senescent cardiomyocytes does not adversely alter cardiac function in aged mice.”
From Length-independent telomere damage drives post-mitotic cardiomyocyte senescence (2019) · cites this paper as Demaria et al, 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cellular senescence, a central hallmark of aging,13,14 encompasses heterogeneous cellular states triggered by prolonged cell stress resulting in the irreversible arrest of proliferation and permanent changes to cell function in vivo.15,16,17,18,19”
From Uncovering the signatures of aging and senescence in the human dorsolateral prefrontal cortex (2026) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, these detrimental effects were neutralized via genetic or pharmacological clearance of senescent cells 27 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, high expression of p16 INK4a in circulating Tcells before treatment, presumably a surrogate biomarker of system-wide senescent cell burden, correlates with severe chemotherapy- induced fatigue in patients with breast cancer, suggesting that senescent cells might contribute to the reduced tolerance of older individuals to anticancer therapies 27 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in mouse models have demonstrated that TIS promotes cardiac dysfunction, inflammation, bone loss, muscle weakness, renal and hepatic failure, haematopoietic insufficiency, and overall frailty 27,111,202 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with cancer, older age (>65 years) is associated with reduced tolerance to anticancer treatment 27 and a greater risk of developing serious AEs 192 , as well as genetic alterations that might lead to reduced sensitivity to treatment; together these features constitute major hurdles for the successful administration of antineoplastic therapies at efficient doses.”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These include increases in local and systemic inflammation and cancer reoccurrence (Demaria et al. 2017).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Demaria et al. 2017
The cited source says what the claim attributes to it.
In the citing paper
“In some cases, these triggers cause fibroblasts to enter a non-proliferative state termed ‘senescence’71, which is distinct from the phenotype of an aged fibroblast.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“For example, DOX-induced systemic senescence was found to promote metastasis in an orthotopic mouse model of breast cancer.”
From Drug repurposing for cancer therapy (2024) · cites this paper as [232]
The cited source says what the claim attributes to it.
In the citing paper
“p16 INK4a expression is considered a common and robust, albeit not necessarily specific, marker of senescence, and its promoter activity and transcriptional activation are extensively exploited as reporters of senescent cells invivo 20,23,27,28 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“Alkylating agents 27,95,96 (for example, cisplatin, cyclophosphamide and temozolomide), topoisomerase inhibitors 27,65,91,95 (such as doxorubicin, etoposide and camptothecin) and γ- irradiation 78 , but also microtubule inhibitors 27,97,98 (for example, paclitaxel) and, to a lesser extent, vinca alkaloids 78 (for example, vincristine), have all been identified as senescence inducers in preclinical”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“In tumour- free mice, exposure to the topoisomerase II inhibitor doxorubicin leads to systemically elevated SASP and functional impairment reminiscent of accelerated ageing, which is only explained in part by direct organ toxicity of this chemotherapeutic agent 27 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“Doxorubicin- induced systemic senescence contributed to breast cancer metastasis in an orthotopic mouse model.”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, high expression of p16 INK4a in circulating Tcells before treatment, presumably a surrogate biomarker of system-wide senescent cell burden, correlates with severe chemotherapy- induced fatigue in patients with breast cancer, suggesting that senescent cells might contribute to the reduced tolerance of older individuals to anticancer therapies 27 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [27]
In the citing paper
“SASP also mediates the harmful effects of senescent cells which accumulate upon chemotherapy treatment as their chronic presence promotes local and systemic inflammation.”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Demaria et al., 2017
In the citing paper
“age-related or therapy-induced senescent cells are mainly linked with secretion of inflammatory factors (Baker et al., 2016; Demaria et al., 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Demaria et al., 2017
In the citing paper
“Elimination of therapy-induced senescent cells can prevent cancer recurrence (Demaria et al., 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Demaria et al., 2017
In the citing paper
“Moreover, senescent cells have been implicated in the adverse effects of some chemotherapeutic regimens as well as in the recurrence of specific neoplasms, at least in mice [969].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [969]
In the citing paper
“Therapy-induced senescence plays an important role in determining the outcome of anti-cancer treatment 40, whilst also being responsible for some of its side effects 41.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [41]
In the citing paper
“whilst also contributing to their side effects 41.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [41]
In the citing paper
“Via the SASP, senescent cells contribute to multiple chronic health conditions associated with inflammaging, e.g., atherosclerosis (16), osteoarthritis (17), cancer (18), myeloid skewing in the bone marrow (19), pulmonary fibrosis (20), Alzheimer’s disease and Parkinson’s disease (21–23), and insulin resistance (24).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [18]
In the citing paper
“These persisting senescent cells have been recently tied to multiple chronic diseases other than atherosclerosis, including diabetes mellitus,85 obesity,85 Alzheimer’s disease,86 heart failure,10,87 idiopathic pulmonary fibrosis,88,89 chronic obstructive pulmonary disease,90 chronic kidney disease,91 cancer,92 and osteoarthritis.93”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [92]
In the citing paper
“However, chronic senescence promotes cancer.92”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [92]
In the citing paper
“and paradoxically tumorigenesis (Demaria et al., 2017).”
From Telomeres and cell senescence—size matters not (2017) · cites this paper as Demaria et al., 2017
In the citing paper
“However, senescence may contribute to reduced patient resilience to cancer therapies”
From Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies (2020) · cites this paper as [67]
In the citing paper
“The use of senotherapeutic drugs could potentially be effective in treating a variety of conditions primarily or secondarily mediated by accumulation of senescent cells [6, 33, 67–87].”
From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [69]
In the citing paper
“The development of a tumor cell population that escapes from senescence and restarts proliferating may contribute to cancer relapse [342].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [342]
In the citing paper
“Senescent cells have also been postulated to mediate resistance to therapy, while contributing to off-target systemic effects and cancer relapse linked to the treatment with standard anticancer regimens.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [200]
In the citing paper
“In the same model, whole-body clearance of p16 + cells generated by doxorubicin treatment reduces signs of systemic frailty and limits tumor recurrence.200”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [200]
In the citing paper
“Indeed, persistent senescent cells may contribute to detrimental short and long-term side effects of treatment, as well as to metastases and relapse (Demaria et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Demaria et al., 2017
In the citing paper
“the elimination of therapy-induced senescent cells reduced several side-effects of chemotherapy and even cancer recurrence in mice14.”
From A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells (2020) · cites this paper as [14]
In the citing paper
“Furthermore, ablation of senescent cells after chemotherapy can prevent or delay cancer relapse and spread to distal tissues.59”
From Paracrine roles of cellular senescence in promoting tumourigenesis (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 1×
“Moreover, senescent cells accumulate with age in several vertebrate organisms (1), and their elimination can delay the onset of several age-associated disorders in mice (3, 4).”
BackgroundAging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 4×
“Moreover, senescent cells accumulate with age in several vertebrate organisms (1), and their elimination can delay the onset of several age-associated disorders in mice (3, 4).”
BackgroundInfluentialSelf-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
Cellular senescence in aging and age-related disease: from mechanisms to therapy
Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Self-citationAn Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Self-citationDoxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,870
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y. G., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,842
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Self-citationInk4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Yin, J., Han, Q., Zhang, J., Liu, Y., Gan, X., Xie, K., Xie, L., & Deng, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14752 · Cited by 195
Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives
Zhang, M., Salas, S. S., Damba, T., Borghesan, M., Demaria, M., & Moshage, H. J. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111572 · Cited by 192
Self-citationSaleh, T., Carpenter, V. J., Tyutyunyk‐Massey, L., Murray, G., Leverson, J. D., Souers, A. J., Alotaibi, M. R., Faber, A. C., Reed, J., Harada, H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12761 · Cited by 190
Cellular senescence and the tumour microenvironment
Takasugi, M., Yoshida, Y., & Ohtani, N. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13268 · Cited by 190
Connecting aging biology and inflammation in the omics era
Walker, K. A., Basisty, N., Wilson, D. M., & Ferrucci, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158448 · Cited by 189
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Bancaro, N., Calì, B., Troiani, M., Elia, A. R., Arzola, R. A., Attanasio, G., Lai, P., Crespo, M., Gürel, B., Pereira, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.004 · Cited by 189
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Survey of senescent cell markers with age in human tissues
Idda, M. L., McClusky, W. G., Lodde, V., Munk, R., Abdelmohsen, K., Rossi, M., & Gorospe, M. (2020) · Aging · doi:10.18632/aging.102903 · Cited by 188
Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs
Kudlová, N., Sanctis, J. B. D., & Hajdúch, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084168 · Cited by 186
Fracture Healing in the Setting of Endocrine Diseases, Aging, and Cellular Senescence
Saul, D., & Khosla, S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac008 · Cited by 185
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
Guccini, I., Revandkar, A., D'Ambrosio, M., Colucci, M., Pasquini, E., Mosole, S., Troiani, M., Brina, D., Sheibani-Tezerji, R., Elia, A. R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.012 · Cited by 185
Ogrodnik, M., Salmonowicz, H., & Gladyshev, V. N. (2019) · Aging Cell · doi:10.1111/acel.12841 · Cited by 184
Paracrine roles of cellular senescence in promoting tumourigenesis
Gonzalez-Meljem, J. M., Apps, J. R., Fraser, H. C., & Martinez-Barbera, J. P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0066-1 · Cited by 183
Tumor cell escape from therapy-induced senescence
Saleh, T., Tyutyunyk-Massey, L., Murray, G. F., Alotaibi, M. R., Kawale, A. S., Elsayed, Z., Henderson, S. C., Yakovlev, V., Elmore, L. W., Toor, A., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.013 · Cited by 182
Chambers, C. R., Ritchie, S., Pereira, B., & Timpson, P. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13042 · Cited by 182
Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy
Hsu, C.-H., Altschuler, S. J., & Wu, L. F. (2019) · Cell · doi:10.1016/j.cell.2019.05.041 · Cited by 181
Anti-senescence compounds: A potential nutraceutical approach to healthy aging
Gurău, F., Baldoni, S., Prattichizzo, F., Espinosa, E., Amenta, F., Procopio, A. D., Albertini, M. C., Bonafè, M., & Olivieri, F. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.001 · Cited by 179
Spatial and Temporal Control of Senescence
Ito, Y., Hoare, M., & Narita, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.07.004 · Cited by 178
Reducing Senescent Cell Burden in Aging and Disease
Pignolo, R. J., Passos, J. F., Khosla, S., Tchkonia, T., & Kirkland, J. L. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.005 · Cited by 177
Mahdy, H. A., Ibrahim, M. K., Metwaly, A. M., Belal, A., Mehany, A. B. M., El‐Gamal, K. M., El-Sharkawy, A., Elhendawy, M. A., Radwan, M. M., ElSohly, M. A., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103422 · Cited by 177
Regulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions
Soto-Gamez, A., Quax, W. J., & Demaria, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.036 · Cited by 175
Self-citationLai, P., Liu, L., Bancaro, N., Troiani, M., Calì, B., Li, Y., Chen, J., Singh, P. K., Arzola, R. A., Attanasio, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.005 · Cited by 174
Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development
Hu, L., Li, H., Zi, M., Li, W., Liu, J., Yang, Y., Zhou, D., Kong, Q., Zhang, Y., & He, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.822816 · Cited by 174
Self-citationOxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis
Wiley, C. D., Sharma, R., Davis, S. S., Lopez-Dominguez, J. A., Mitchell, K. P., Wiley, S., Alimirah, F., Kim, D. E., Payne, T., Rosko, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.008 · Cited by 173
Self-citationvan Vliet, T., Varela-Eirin, M., Wang, B., Borghesan, M., Brandenburg, S. M., Franzin, R., Evangelou, K., Seelen, M., Gorgoulis, V., & Demaria, M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.018 · Cited by 172
Self-citationGalactose‐modified duocarmycin prodrugs as senolytics
Guerrero, A., Guiho, R., Herranz, N., Uren, A., Withers, D. J., Martínez‐Barbera, J. P., Tietze, L. F., & Gil, J. (2020) · Aging Cell · doi:10.1111/acel.13133 · Cited by 172
Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies
Lucas, V., Cavadas, C., & Aveleira, C. A. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000622 · Cited by 172
Basu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 168
Self-citationLow-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
Cifuentes, M., Verdejo, H., Castro, P., Corvalán, A. H., Catterina Ferreccio, R., Quest, A. F. G., Kogan, M. J., & Lavandero, S. (2024) · Physiology · doi:10.1152/physiol.00021.2024 · Cited by 167
Yasuda, T., Koiwa, M., Yonemura, A., Miyake, K., Kariya, R., Kubota, S., Yokomizo-Nakano, T., Yasuda-Yoshihara, N., Uchihara, T., Itoyama, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108779 · Cited by 165
Hwang, H. J., Lee, Y.-R., Kang, D., Lee, H., Seo, H. R., Ryu, J., Kim, Y.-N., Ko, Y., Park, H. J., & Lee, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.019 · Cited by 164
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
Self-citationTumour Cell Secretome in Chemoresistance and Tumour Recurrence
Madden, E. C., Gorman, A. M., Logue, S. E., & Samali, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.020 · Cited by 161
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Expression of p16INK4a is a biomarker of chondrocyte aging but does not cause osteoarthritis
Diekman, B. O., Sessions, G. A., Collins, J. A., Knecht, A. K., Strum, S. L., Mitin, N. K., Carlson, C. S., Loeser, R. F., & Sharpless, N. E. (2018) · Aging Cell · doi:10.1111/acel.12771 · Cited by 158
Self-citationNacarelli, T., Fukumoto, T., Zundell, J. A., Fatkhutdinov, N., Jean, S., Cadungog, M. G., Borowsky, M. E., & Zhang, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2830 · Cited by 158
Zhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04010-4 · Cited by 157
A null mutation in SERPINE1 protects against biological aging in humans
Khan, S. S., Shah, S. J., Klyachko, E., Baldridge, A. S., Eren, M., Place, A. T., Aviv, A., Puterman, E., Lloyd-Jones, D. M., Heiman, M., et al. (2017) · Science Advances · doi:10.1126/sciadv.aao1617 · Cited by 157
Role of gut microbiota in liver disease
Albhaisi, S. A. M., Bajaj, J. S., & Sanyal, A. J. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00118.2019 · Cited by 155
Neutrophils in aging and aging‐related pathologies
Avondt, K. V., Strecker, J., Tulotta, C., Minnerup, J., Schulz, C., & Soehnlein, O. (2022) · Immunological Reviews · doi:10.1111/imr.13153 · Cited by 155
Chatsirisupachai, K., Palmer, D. H., Ferreira, S., & de Magalhães, J. P. (2019) · Aging Cell · doi:10.1111/acel.13041 · Cited by 152
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 146
Xu, Q., Long, Q., Zhu, D., Fu, D., Zhang, B., Han, L., Qian, M., Guo, J., Xu, J., Cao, L., et al. (2019) · Aging Cell · doi:10.1111/acel.13027 · Cited by 145
Self-citationThe role of cellular senescence and SASP in tumour microenvironment
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2023) · The FEBS Journal · doi:10.1111/febs.16381 · Cited by 144
Colucci, M., Sarill, M., Maddalena, M., Valdata, A., Troiani, M., Massarotti, M., Bolis, M., Bressan, S., Kohl, A., Robesti, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.015 · Cited by 143
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Antoun, N. B., & Chioni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512222 · Cited by 141
Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0108-0 · Cited by 140
Mitochondrial peptides modulate mitochondrial function during cellular senescence
Kim, S., Mehta, H. H., Wan, J., Kuehnemann, C., Chen, J., Hu, J., Hoffman, A. R., & Cohen, P. (2018) · Aging · doi:10.18632/aging.101463 · Cited by 140
SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells
Wiley, C. D., Liu, S., Limbad, C., Zawadzka, A. M., Beck, J., Demaria, M., Artwood, R., Alimirah, F., Lopez-Dominguez, J.-A., Kuehnemann, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.049 · Cited by 137
Self-citationPoblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99852-2 · Cited by 137
Exposome and unhealthy aging: environmental drivers from air pollution to occupational exposures
Pándics, T., Major, D., Fazekas‐Pongor, V., Szarvas, Z., Péterfi, A., Mukli, P., Gulej, R., Ungvari, A., Fekete, M., Tompa, A., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00913-3 · Cited by 137
The microbiome and hepatobiliary-pancreatic cancers
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., Hashimoto, D., Baba, Y., Yamashita, Y., Yoshida, N., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.001 · Cited by 136
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 136
The immuno-oncological challenge of COVID-19
Derosa, L., Melenotte, C., Griscelli, F., Gachot, B., Marabelle, A., Kroemer, G., & Zitvogel, L. (2020) · Nature Cancer · doi:10.1038/s43018-020-00122-3 · Cited by 136
Shahbandi, A., Rao, S. G., Anderson, A. Y., Frey, W. D., Olayiwola, J. O., Ungerleider, N., & Jackson, J. G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0564-6 · Cited by 135
Calcium signaling and cellular senescence
Martin, N., & Bernard, D. (2017) · Cell Calcium · doi:10.1016/j.ceca.2017.04.001 · Cited by 133
Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma
Salam, R., Saliou, A., Bielle, F., Bertrand, M., Antoniewski, C., Carpentier, C., Alentorn, A., Capelle, L., Sanson, M., Huillard, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36124-9 · Cited by 132
Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells
Mikuła‐Pietrasik, J., Niklas, A. A., Uruski, P., Tykarski, A., & Książek, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03261-8 · Cited by 131
Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
Maggiorani, D., Lê, O., Lisi, V., Landais, S., Moquin‐Beaudry, G., Lavallée, V., Decaluwe, H., & Beausejour, C. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46769-9 · Cited by 130
Targeting Senescent Cells for a Healthier Aging: Challenges and Opportunities
Song, S., Tchkonia, T., Jiang, J., Kirkland, J. L., & Sun, Y. (2020) · Advanced Science · doi:10.1002/advs.202002611 · Cited by 129
Therapy-Induced Senescence Drives Bone Loss
Yao, Z., Murali, B., Ren, Q., Luo, X., Faget, D. V., Cole, T., Ricci, B., Thotala, D., Monahan, J., van Deursen, J. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2348 · Cited by 129
Ionizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review
Nguyen, H. Q., To, N. H., Zadigue, P., Kerbrat, S., TAILLE, A. D. L., Gouvello, S. L., & Belkacémi, Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.012 · Cited by 129
Kang, C. (2019) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2019.0298 · Cited by 129
Meng, J., Li, Y., Wan, C., Sun, Y., Dai, X., Huang, J., Hu, Y. W., Gao, Y., Wu, B., Zhang, Z., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146334 · Cited by 129
Cellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling
Alimirah, F., Pulido, T., Valdovinos, A., Alptekin, S., Chang, E., Jones, E., Diaz, D. A., Flores, J., Velarde, M. C., Demaria, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0108 · Cited by 128
Self-citationCellular senescence: a double-edged sword in cancer therapy
Xiao, S., Qin, D., Hou, X., Tian, L., Yu, Y., Zhang, R., Lyu, H., Guo, D. S., Chen, X., Zhou, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1189015 · Cited by 128
Oxidation resistance 1 is a novel senolytic target
Zhang, X., Zhang, S., Liu, X., Wang, Y., Chang, J., Zhang, X., Mackintosh, S. G., Tackett, A. J., He, Y., Lv, D., et al. (2018) · Aging Cell · doi:10.1111/acel.12780 · Cited by 127
Self-citationEmerging use of senolytics and senomorphics against aging and chronic diseases
Martel, J., Ojcius, D. M., Wu, C., Peng, H., Voisin, L., Perfettini, J., Ko, Y., & Young, J. D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21702 · Cited by 127
Cellular senescence and cardiovascular diseases: moving to the “heart” of the problem
Evangelou, K., Vasileiou, P. V. S., Papaspyropoulos, A., Hazapis, O. G., Petty, R., Demaria, M., & Gorgoulis, V. G. (2022) · Physiological Reviews · doi:10.1152/physrev.00007.2022 · Cited by 127
Self-citationMechanisms of Normal Tissue Injury From Irradiation
Citrin, D. E., & Mitchell, J. B. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.04.001 · Cited by 126
The Paradoxical Role of Cellular Senescence in Cancer
Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722205 · Cited by 125
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 125
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Wiley, C. D., Schaum, N., Alimirah, F., Lopez-Dominguez, J. A., Orjalo, A. V., Scott, G., Desprez, P.-Y., Benz, C., Davalos, A. R., & Campisi, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20000-4 · Cited by 124
Self-citationCellular Senescence and the Immune System in Cancer
Prieto, L. I., & Baker, D. J. (2019) · Gerontology · doi:10.1159/000500683 · Cited by 124
Yabluchanskiy, A., Tarantini, S., Balasubramanian, P., Kiss, T., Csípő, T., Fülöp, G., Lipécz, Á., Ahire, C., DelFavero, J., Nyúl‐Tóth, Á., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00154-8 · Cited by 124
Self-citationZhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123
Self-citationCellular senescence, senescence-associated secretory phenotype, and chronic kidney disease
Wang, W.-J., Cai, G.-Y., & Chen, X.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.17327 · Cited by 121
He, Y., Li, W., Lv, D., Zhang, X., Zhang, X., Ortiz, Y. T., Budamagunta, V., Campisi, J., Zheng, G., & Zhou, D. (2020) · Aging Cell · doi:10.1111/acel.13117 · Cited by 120
Self-citationPreclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Galiana, I., Lozano‐Torres, B., Sancho, M., Alfonso, M., Bernardos, A., Bisbal, V., Serrano, M., Martínez‐Máñez, R., & Orzáez, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.045 · Cited by 119
Radiation-induced astrocyte senescence is rescued by Δ133p53
Turnquist, C., Beck, J. A., Horikawa, I., Obiorah, I. E., Von Muhlinen, N., Vojtesek, B., Lane, D. P., Grunseich, C., Chahine, J. J., Ames, H. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz001 · Cited by 118
Zumerle, S., Sarill, M., Saponaro, M., Colucci, M., Contu, L., Lazzarini, E., Sartori, R., Pezzini, C., Rinaldi, A. M., Scanu, A., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00663-7 · Cited by 117
Anticancer potential of allicin: A review
Catanzaro, E., Canistro, D., Pellicioni, V., Vivarelli, F., & Fimognari, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106118 · Cited by 116
Dual-Locked Enzyme-Activatable Bioorthogonal Fluorescence Turn-On Imaging of Senescent Cancer Cells
Wang, X., Liew, S. S., Huang, J., Hu, Y., Wei, X., & Pu, K. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c07286 · Cited by 115
The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2
Chaib, S., López-Domínguez, J. A., Lalinde-Gutiérrez, M., Prats, N., Marin, I., Boix, O., García-Garijo, A., Meyer, K., Muñoz, M. I., Aguilera, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00712-x · Cited by 114
Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls
Owens, W. A., Walaszczyk, A., Spyridopoulos, I., Dookun, E., & Richardson, G. D. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111540 · Cited by 114
Glioblastoma as an age-related neurological disorder in adults
Kim, M., Ladomersky, E., Mozny, A., Kocherginsky, M., O’Shea, K., Reinstein, Z. Z., Zhai, L., Bell, A., Lauing, K. L., Bollu, L. R., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab125 · Cited by 114
Cellular Senescence and Ageing: Mechanisms and Interventions
Mylonas, A., & O’Loghlen, A. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.866718 · Cited by 114
Pérez, K., Ciotlos, S., McGirr, J., Limbad, C., Doi, R., Nederveen, J. P., Nilsson, M. I., Winer, D. A., Evans, W. J., Tarnopolsky, M. A., et al. (2022) · Aging · doi:10.18632/aging.204435 · Cited by 114
Self-citationPharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity
Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M. (2022) · The EMBO Journal · doi:10.15252/embj.2021108946 · Cited by 113
Self-citationTargeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 113
Jurj, A. M., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02484-1 · Cited by 113
Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 111
Mahoney, S. A., Venkatasubramanian, R., Darrah, M. A., Ludwig, K. R., VanDongen, N. S., Greenberg, N., Longtine, A. G., Hutton, D. A., Brunt, V. E., Campisi, J., et al. (2023) · Aging Cell · doi:10.1111/acel.14060 · Cited by 111
Self-citationDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
Biological functions of therapy-induced senescence in cancer
Fitsiou, E., Soto-Gamez, A., & Demaria, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.021 · Cited by 105
Self-citation
Metadata
- Authors
- Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., Alston, S., Academia, E. C., Kilmarx, S., Valdovinos, A., Wang, B., de Bruin, A., Kennedy, B. K., Melov, S., Zhou, D., Sharpless, N. E., Muss, H., & Campisi, J.
- Affiliations
- University Medical Center Groningen (NL)
- 1Buck Institute for Research on Aging, Novato, California.
- University of Arkansas for Medical Sciences (US)
- Buck Institute for Research on Aging (US)
- 4HealthSpan Diagnostics, Research Triangle Park, North Carolina.
- University of North Carolina at Chapel Hill (US)
- 6Department of Pathobiology, University of Utrecht, Utrecht, the Netherlands.
- Corresponding author
- Demaria, Marco
- Campisi, Judith
- ORCID
- Venue
- Cancer Discovery
- Published
- 2017-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 165-176
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5296251
- OpenAlex
- W2561396377
- Cited by
- 1,338
- References
- 34
- Citations by year
- 2026: 113 · 2025: 153 · 2024: 164 · 2023: 176 · 2022: 198 · 2021: 152 · 2020: 159 · 2019: 105 · 2018: 79 · 2017: 38
- FWCI
- 59.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- UNC Libraries
- Funders
- American-Italian Cancer Foundation
- National Institutes of Health (5r01ag024379-15, AG009909, AG017242, AG041122)
- National Institute on Aging (R56AG009909, R01-AG024379, R37AG009909, P01AG041122, P01AG017242)
- National Cancer Institute (R01CA122023, R01CA166347, R01CA203023, R01CA163896, P30CA016086)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- cellular senescence, therapy-induced senescence, chemotherapy toxicity, senescence-associated secretory phenotype, senolytics, senescent cell elimination, inflammation, tumor recurrence, myelosuppression, cardiotoxicity, chemotherapy-induced fatigue, T cells, genotoxic chemotherapy, transgenic mouse model
- MeSH terms
- Animals, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Mice, Transgenic, Neoplasm Recurrence, Local, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
